ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01EJ01 | B | Ruxolitinib - 5mg | 7999 | 57314/1 | JAKAVI | 5mg | 56 | Tablet | Oral | Khalil Fattal & Fils S.A.L. | Novartis Pharma Stein AG | Switzerland | 2,611,633 L.L | 2.44 | E2 | Novartis Pharma AG | Switzerland | 2/5/2024 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01EJ01 | G | Ruxolitinib - 5mg | 11479 | 152320/1 | CELEZON | 5mg | 56 | Tablet | Oral | Droguerie de l'Union | The Arab Pharmaceutical Manufacturing PSC | Jordan | 1,566,974 L.L | 2.44 | E2 | Hikma Pharmaceuticals | Jordan | 2/5/2024 | |
L01EJ01 | B | Ruxolitinib - 5mg | 7999/945 | 57314/1 | JAKAVI | 5mg | 56 | Tablet | Oral | Khalil Fattal & Fils S.A.L. | Novartis Pharma Stein AG | Switzerland | 159,222,240 L.L | 2.44 | E2 | Novartis Pharma AG | Switzerland | 2/5/2024 | 0 |
L01EJ01 | G | Ruxolitinib - 5mg | 11479/945 | 152320/1 | CELEZON | 5mg | 56 | Tablet | Oral | Droguerie de l'Union | The Arab Pharmaceutical Manufacturing PSC | Jordan | 95,532,998 L.L | 2.44 | E2 | Hikma Pharmaceuticals | Jordan | 2/5/2024 | 0 |